ADA and breast cancer: Therefore, the aim of this work was to evaluate the antitumour potential of a specific inhibitor of total ADA, 2′deoxycoformycin (dCF) in mouse breast cancer models and human breast cancer cell lines as well as to estimate the activities of both ADA isoenzymes in malignant and benign breast neoplastic cells, immune cells and endothelial cells.